Esperion Therapeutics, Inc. - ESPR

SEC Filings Our ESPR Tweets

About Gravity Analytica

Recent News

10.07.2026 - Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
09.30.2026 - Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
05.26.2026 - Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
05.14.2026 - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05.13.2026 - Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
05.01.2026 - Esperion to be Acquired by ARCHIMED
04.23.2026 - Esperion to Report First Quarter 2026 Financial Results on May 7
04.02.2026 - Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
03.31.2026 - Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
03.30.2026 - Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

Recent Filings